Skip Navigation



JAC Advance Access published online on April 21, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn178
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/2/345    most recent
dkn178v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lechner, D.
Right arrow Articles by Bucar, F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lechner, D.
Right arrow Articles by Bucar, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis

Doris Lechner1, Simon Gibbons2 and Franz Bucar1,*

1 Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl-Franzens-University of Graz, Universitaetsplatz 4/I, A-8010 Graz, Austria 2 Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK

Received 27 November 2007; returned 30 January 2008; revised 28 February 2008; accepted 1 April 2008

* Corresponding author. Tel: +43-316-3805531; Fax: +43-316-3809860; E-mail: franz.bucar{at}uni-graz.at

Background: One-third of the world's population is infected with the dormant tuberculosis bacillus, and there have been no new antimycobacterial compounds with new modes of action for over 30 years. Extensively drug-resistant tuberculosis is resistant to first- and second-line drugs, which can have severe side effects, and requires the breakthrough of new antituberculotics and resistance-modifying agents. Efflux pumps can cause multidrug resistance and have recently evoked much interest as promising new targets in antimicrobial therapy.

Objectives: The study was performed to set up an ethidium bromide (EtBr) efflux assay in Mycobacterium smegmatis mc2155 for testing plant natural compounds as mycobacterial efflux pump inhibitors (EPIs).

Methods: After determining the MICs of the putative EPIs, they were tested for synergistic effects with EtBr prior to the efflux assay.

Results: We established an EtBr efflux assay in M. smegmatis mc2155. The isoflavone biochanin A exhibited efflux pump inhibiting activity comparable to that of verapamil. The flavone luteolin and the stilbene resveratrol were less active.

Conclusions: A new assay was established to observe the EtBr efflux in M. smegmatis and was applied to evaluate plant phenolic compounds. Our results highlighted that the isoflavonoid biochanin A exhibited better EPI activities than other flavonoids in mycobacteria.

Key Words: isoflavonoids , biochanin A , efflux pumps , mycobacteria


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.